Hygeia Therpaeutics, Inc.

 

NEWS

November 10, 2010
Completion of a Series of Preclinical Studies for Lead "Soft" Estrogen HYG-102

April 19, 2010
Completion of $1.0 million in Series A Financing

September 14, 2009
Elkan Gamzu Appointed Chairman of Hygeia Therapeutics' Board of Directors

July 20, 2009
Acquision of a Series of "Soft" Anti-androgens for Topical Use

November 2007
Acquisition of a Series of "Soft" Estrogens for Topical Use

Forward-Looking Statements

These releases contain forward-looking statements that involve risks and uncertainties. Hygeia cautions readers that any forward-looking information is not a guarantee of future performance and actual results could differ materially from those contained in the forward-looking information. Words such as "expect," "estimate," "project," "potential," and similar expressions are intended to identify such forward-looking statements. Such forward looking statements include, but are not limited to, statements about Hygeia and its plans, objectives, expectations and intentions and other statements that are not historical facts. Hygeia product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; and positive results in clinical trials may not be sufficient to obtain FDA approval. There can be no assurance that any product in the company's product pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Hygeia disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Copyright ©2010 Hygeia Therapeutics, Inc. All Rights Reserved.